The American Society of Clinical Oncology released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid–or block grants–could have on patients with cancer.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
